Polysaccharides are macromolecular compounds formed by more than 10 monosaccharide molecules linked by glycosidic bonds. Polysaccharides have a wide range of sources, high safety and low toxicity, with a variety of biological activities, such as anti-tumor, anti-virus, immune regulation, lowering blood glucose, and lowering blood lipids. Type 2 diabetes mellitus(T2 DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance and low inflammation. In recent years, the treatment of T2 DM with polysaccharide has become a research hotspot. Polysaccharides can not only make up for the side effects such as hypoglycemia, weight gain, gastrointestinal injury caused by long-term treatment of acarbose, biguanidine and sulfonylurea, but also play an effective role in reducing glucose by regulating glucose metabolism, oxidative stress, inflammatory response, intestinal flora, etc. In this paper, the research progress of polysaccharides in the treatment of T2 DM was reviewed. In addition, the hot spots such as the hypoglycemic activity of polysaccharides with structural modifications were summarized, providing theoretical guidance for the development of active polysaccharide hypoglycemic medicines and the further study of action mechanism.
Blood Glucose ; Diabetes Mellitus, Type 2/drug therapy* ; Humans ; Hypoglycemic Agents/pharmacology* ; Insulin Resistance ; Polysaccharides

Animals ; Blood Glucose ; Cucurbita ; chemistry ; Diabetes Mellitus, Experimental ; drug therapy ; Hypoglycemic Agents ; pharmacology ; Lipids ; blood ; Oxidative Stress ; Polysaccharides ; pharmacology ; Rats

Animals ; Blood Glucose ; drug effects ; Crystallization ; Cyclohexanes ; chemistry ; pharmacology ; Female ; Hyperglycemia ; blood ; Hypoglycemic Agents ; pharmacology ; Male ; Mice ; Mice, Inbred ICR ; Phenylalanine ; analogs & derivatives ; chemistry ; pharmacology ; X-Ray Diffraction

AIMTo investigate the effects of pumpkin polysaccharides on blood glucose and lipids levels in diabetic rats.

METHODSDiabetic rats induced by alloxan through intraperitoneal injection were randomly divided into three groups, diabetes, xiaoke pill and pumpkin polysaccharides group, according to weight and blood glucose level. And the normal control group was founded at the same time. The normal control group and diabetes group were lavaged with distilled water, other two groups were respectively lavaged with xiaoke pill or pumpkin polysaccharides. Weighed once a week, and analyzed fasting blood glucose, total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, and free fatty acid level in serum after 4 weeks.

RESULTSIn diabetes group, weight and high density lipoprotein level decreased, and fasting blood glucose, total cholesterol, triglyceride, low density lipoprotein, and free fatty acid level in serum increased significantly. But, all of the indexes changed oppositely in xiaoke pill group and pumpkin polysaccharides group, and effects of pumpkin polysaccharides were better.

CONCLUSIONPumpkin polysaccharides can increase the weight, decrease the blood glucose and lipids levels in diabetic rats, and have some good effects to diabetes and diabetes complications.

Animals ; Blood Glucose ; metabolism ; Cucurbita ; chemistry ; Diabetes Mellitus, Experimental ; blood ; Hypoglycemic Agents ; pharmacology ; Lipids ; blood ; Male ; Polysaccharides ; pharmacology ; Rats ; Rats, Wistar

AIM: The hypoglycemic and hypolipidemic effects of the methanol extract of Brassica oleracea var. capitata (MEB) was evaluated in alloxan-induced diabetic rabbits. METHOD: The study was conducted on twenty-eight healthy white rabbits of either sex. All animals were equally divided into four groups. After confirmation of hyperglycemia, the animals of the treated and standard groups were administered MEB (500 mg·kg(-1)) and glibenclamide (10 mg·kg(-1)), respectively for 15 and 30 days. The animals of the normal and diabetic controls received normal saline 1 mL/day equivalent to the volume of doses given to the test and standard animals. Biochemical tests were performed at the end of dosing, i.e. the 16(th) and 31(st) days. RESULTS: The MEB revealed a decrease of 106.6 mg·dL(-1) in fasting blood glucose as compared to diabetic control, which was almost comparable to glibenclamide; both of these changes were highly significant. The decrease in total cholesterol and low density lipoprotein was 94.3 and 96.5 mg·dL(-1), respectively, whereas the high-density lipoprotein was increased by 26.7 mg·dL(-1), as compared to diabetic control. All of the changes in lipid profile were statistically significant. CONCLUSION These results suggest the potential of MEB as a hypoglycemic and hypolipidemic agent.
Animals ; Blood Glucose ; metabolism ; Brassica ; Cholesterol ; blood ; Diabetes Mellitus, Experimental ; blood ; drug therapy ; Female ; Hypoglycemic Agents ; pharmacology ; therapeutic use ; Hypolipidemic Agents ; pharmacology ; therapeutic use ; Lipoproteins ; blood ; Male ; Phytotherapy ; Plant Extracts ; pharmacology ; therapeutic use ; Rabbits ; Triglycerides ; blood

OBJECTIVES: To investigate the effects of saffron aqueous extract (SE) on blood glucose, lipid and pancreatic tissue in streptozocin-induced diabetes mice. METHODS: Diabetes mellitus mice were established by intraperitoneal injection of streptozocin (60 mg/kg) for two consecutive days. The 30 well-established diabetes mice were randomly divided into three groups(=10):diabetic mellitus (DM) group, SE treated (SE) group and positive control (metformin hydrochloride, MH) group. Another ten normal mice were selected as normal control (NC) group. The mice in SE and MH groups were intragastrically administered with SE 100 mg/kg or MH 100 mg/kg once a day for 6 weeks, mice in DM and NC were given normal saline. The amount of food-intake, water consumption and body weight were measured weekly, the changes of the indicators including fasting blood glucose (FBG), oral glucose-tolerance test (OGTT), glycated serum protein (GSP), insulin (INS) and blood lipid were determined after 6 weeks of continuous administration. The pathologic changes in the pancreas tissues were detected by HE staining. RESULTS: Compared with the normal control group, the amount of food-intake, water consumption, area under the curve, FBG, GSP, and total cholesterol (TC) were significantly increased, while fasting weight, INS and high density lipoprotein cholesterol (HDL-c) were dramatically decreased in DM group. Compared with DM group, the water consumption, FBG, area under the curve and TC in SE group were starkly declined with a notable elevation of HDL-c and INS. In addition, the biopsy from DM mice showed the structure of pancreas islet was destroyed and reduced, and vascular proliferation with irregular shape. The damaged pancreas was obviously repaired by giving SE. CONCLUSIONS The saffron aqueous extract had efficacy on blood glucose and blood lipids reduction, improvement on damaged pancreas in streptozocininduced diabetic mice, which suggested that saffron could be used for the treatment in diabetes.
Animals ; Blood Glucose ; Crocus ; chemistry ; Diabetes Mellitus, Experimental ; chemically induced ; drug therapy ; Hypoglycemic Agents ; pharmacology ; Insulin ; blood ; Mice ; Plant Extracts ; pharmacology ; Random Allocation ; Streptozocin

To study insulino-mimetic effects of bis(alpha-furancarboxylato) oxovanadium (IV) (BFOV), a orally active antidiabetic vanadyl complex, on glucose uptake and lipogenesis in isolated rat adipocytes were determined by using 2-deoxy-D-[3H]-glucose and D-[3H]-glucose, respectively. Lipolysis was assayed by free fatty acids (FFA) released from isolated rat adipocytes treated with epinephrine. The results showed that BFOV, similar to insulin, concentration-dependently significantly enhanced the uptake of 2-deoxy-D-[3H]-glucose and the transformation from D-[3H]-glucose to lipid in isolated rat adipocytes, with the EC50 values of (0.31 +/- 0.08) mmol L(-1) and (0.49 +/- 0.12) mmol L(-1), respectively. Moreover, BFOV markedly inhibited FFA release from isolated rat adipocytes treated with epinephrine, and the IC50 value was (0.30 +/- 0.20) mmol L(-1). BFOV had insulino-mimetic effects such as enhancing glucose uptake and lipogenesis, as well as inhibiting lipolysis.
Adipocytes ; drug effects ; metabolism ; Animals ; Blood Glucose ; drug effects ; Hypoglycemic Agents ; pharmacology ; Insulin ; pharmacology ; Lipogenesis ; drug effects ; Male ; Organometallic Compounds ; pharmacology ; Rats ; Rats, Sprague-Dawley

The present study aimed to evaluate the anti-diabetic property of peanut shell polyphenol extracts (PSPEs). Diabetic rats were oral-administrated with PSPE at doses of 50, 100, and 200 mg/kg body weight (BW) per day for 28 consecutive days, with metformin (Met) as a positive control. The results showed that, similar to the Met treatment, administration of PSPE caused significant decreases in food intake, water intake, fasting blood glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and methane dicarboxylic aldehyde in serum, and significant increases in BW, insulin level, high-density lipoprotein cholesterol, superoxide dismutase, glutathione, and liver glycogen. Further, glucose tolerance was markedly improved in the PSPE-treated diabetic groups. Histopathological results showed that PSPE improved cellular structural and pathological changes in liver, kidney, and pancreatic islets. Collectively, the results indicated that the hypoglycemic effects of PSPE on high-fat diet/streptozotocin (HFD/STZ)-induced diabetes are comparable to Met, though their exact mechanism actions are still under investigation. Therefore, the current study suggests that PSPE could be a potential health-care food supplement in the management of diabetes.
Animals ; Arachis/chemistry* ; Diabetes Mellitus, Experimental/pathology* ; Hypoglycemic Agents/pharmacology* ; Lipids/blood* ; Liver/pathology* ; Male ; Oxidative Stress/drug effects* ; Plant Extracts/pharmacology* ; Polyphenols/pharmacology* ; Rats ; Rats, Wistar ; Streptozocin

OBJECTIVETo observe pharmacological difference between ultra-fine particles of six ingredient Rehmannia pill and traditional six ingredient Rehmannia pill.

METHODPharmacokinetic index was measured by death rate, and pharmacology actions were compared by anti-fatigue, hypoglycemic, clearance rate of charcoal particle, hypoxia resistance and serum hemolysin concentration experiment.

RESULTDose-effection was significant and pharmacology actions were more than traditional six ingredient Rehmannia pill in six ingredient Rehmannia pill.

CONCLUSIONUltra-fine particles of six ingredient Rehmannia pill are better than traditional six ingredient Rehmannia pill in bioavailability and pharmacology actions, and the weight of pill is reduced while efficacy is enhenced by ultra-fine particles.

Animals ; Biological Availability ; Drugs, Chinese Herbal ; pharmacokinetics ; pharmacology ; Fatigue ; drug therapy ; Hemolysin Proteins ; blood ; Hypoglycemic Agents ; pharmacology ; Male ; Metabolic Clearance Rate ; Mice ; Plants, Medicinal ; chemistry ; Powders ; Rehmannia ; chemistry

Dipeptidyl peptidase-4 (DPP-4) inhibitors are promising new antidiabetic drugs. It had been proposed that DPP-4 inhibitors exert their antidiabetic effect by inhibiting the degradation of glucagon-like peptide 1(GLP-1) . However, new evidence has shown that the increase of GLP-1 is not notable after the use of these drugs in patients with type 2 diabetes. Therefore, the specific mechanisms via which DPP-4 inhibitors in controlling blood glucose has became questionable. In recent years, studies have revealed many possible mechanisms through which DPP-4 inhibitors regulate glycemia: DPP-4 inhibitors may selectively reduce DPP-4 activity in the intestine, causing the increase of portal plasma GLP-1 level and thus promoting the release of insulin via nerve reflex;also, they may decrease the cleavage product of GLP-1 and reduce the degradation of other bioactive peptides.
Blood Glucose ; metabolism ; Diabetes Mellitus, Type 2 ; drug therapy ; Dipeptidyl-Peptidase IV Inhibitors ; pharmacology ; Glucagon-Like Peptide 1 ; drug effects ; metabolism ; Humans ; Hypoglycemic Agents ; pharmacology